二级导航
招生简章
博士生导师
硕士生导师
培养方案
奖项介绍
研究生会
 
  石虎兵

 

石虎兵 教授

个人简介:

石虎兵,教授、博士生导师,2001年毕业于吉林大学,获本科、硕士学位;2007年毕业于清华大学,获得博士学位;后在美国加州大学洛杉矶分校从事肿瘤分子靶向治疗及耐药性机理研究。2015年入选国家“青年千人”计划。研究期间共发表研究论文20篇,影响因子共计358.2,被引用3020次,撰写专著1项,以第一作者或共同第一作者身份共发表论文9篇,包括:Nature1篇),Cell 1篇),Cancer Cell 1篇),Nature Communications1篇),Cancer Discovery3篇,影响因子19.5),Blood1篇,国内发表、封面文章),Cancer Research1篇),影响因子共计186.8,被引用1855次。

课题组未来致力于以分子靶向治疗和免疫治疗为核心的肿瘤精确个体化治疗,充分的利用临床资源,结合最新高通量分析技术,系统的研究肿瘤治疗机制,鉴定开发新的治疗靶点,推动制药公司新药研发以及联合用药的开发,促进临床治疗方案的优化,最大限度的惠及肿瘤患者。

主要研究方向:

1.  精准个体化治疗,

2.  肿瘤分子靶向治疗,

3.  肿瘤免疫治疗,

4.  生物信息学、数据分析。

代表性论文:

1.    Hubing Shi, Yujie Huang, Hao Zhou, Xiaomin Song, Shaopeng Yuan, Yan Fu, & Yongzhang Luo (2007). “Nucleolin is a Receptor that Mediates Antiangiogenic and Anti-tumor Activity of Endostatin” Blood 110(8):2899-2906 (Featured in Cover).

2.    Ramin Nazarian*, Hubing Shi*, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant McArthur, Jeffrey A. Sosman, Antoni Ribas & Roger S. Lo (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468(7326):973-7.

*These authors contributed equally to this work.

3.    Hubing Shi, Xiangju Kong, Antoni Ribas, and Roger S. Lo (2011) Combinational treatments that overcome PDGFRb-driven resistance of melanoma cells to V600EB-Raf inhibition. Cancer Res. 71(15):5067-74.

4.    Poulikos I. Poulikakos, Yogindra Persaud, Manickam Janakiraman, Xiangju Kong, Charles Ng, Gatien Moriceau, Hubing Shi, Mohammad Atefi, Bjoern Titz, May Tal Gabay, Maayan Salton, Kimberly B. Dahlman, Madhavi Tadi, Jennifer A. Wargo, Keith T. Flaherty, Mark C. Kelley, Tom Misteli, Paul B. Chapman, Jeffrey A. Sosman, Thomas G. Graeber, Antoni Ribas, Roger S. Lo, Neal Rosen & David B. Solit (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480(7377):387-90.

5.    Hubing Shi, Gatien Moriceau*, Xiangju Kong*, Mi-Kyung Lee*, Hane Lee, Richard C. Koya, Charles Ng, Thinle Chodon, Richard A. Scolyer, Kimberly B. Dahlman, Jeffrey A. Sosman, Richard F. Kefford, Georgina V. Long, Stanley F. Nelson, Antoni Ribas & Roger S. Lo (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3:724.

6.    Hubing Shi*, Gatien Moriceau*, Xiangju Kong, Richard C. Koya, Ramin Nazarian, Gulietta M. Pupo, Antonella Bacchiocchi, Kimberly B. Dahlman, Bartosz Chmielowski, Jeffrey A. Sosman, Ruth Halaban, Richard F. Kefford, Georgina V. Long, Antoni Ribas & Roger S. Lo (2012) Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discov. 2(5):414-424.

     *These authors contributed equally to this work.

7.    Agnieszka Gembarska, Flavie Luciani, Clare Fedele, Elisabeth A Russell, Michael Dewaele, Stéphanie Villar, Aleksandra Zwolinska, Sue Haupt, Job de Lange, Dana Yip, James Goydos, Jody J Haigh, Ygal Haupt, Lionel Larue, Aart Jochemsen, Hubing Shi, Gatien Moriceau, Roger S Lo, Ghanem Ghanem, Mark Shackleton, Federico Bernal & Jean-Christophe Marine (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine 18:1239–1247.

8.    Hubing Shi*, Aayoung Hong*, Xiangju Kong, Richard C. Koya, Chunying Song, Gatien Moriceau, Willy Hugo, Clarissa C. Yu, Charles Ng, Thinle Chodon, Richard A. Scolyer, Richard F. Kefford, Antoni Ribas, Georgina V. Long, and Roger S. Lo (2014) A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discov. 4:69-79.

     *These authors contributed equally to this work.

9.    Hubing Shi*, Willy Hugo*, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley,Richard F. Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, and Roger S. Lo (2014) Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discov. 4:80-93.

     *These authors contributed equally to this work.

10. Gatien Moriceau*, Willy Hugo*, Aayoung Hong*, Hubing Shi*, Xiangju Kong, C Yu Clarissa, Richard C Koya, Ahmed A Samatar, Negar Khanlou, Jonathan Braun, Kathleen Ruchalski, Heike Seifert, James Larkin, Kimberly B Dahlman, Douglas B Johnson, Alain Algazi, Jeffrey A Sosman, Antoni Ribas, and Roger S Lo (2015) Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27(2):240-56.

     *These authors contributed equally to this work.

11. Anna C Obenauf, Yilong Zou, Andrew L Ji, Sakari Vanharanta, Weiping Shu, Hubing Shi, Xiangju Kong, Marcus C Bosenberg, Thomas Wiesner, Neal Rosen, Roger S Lo, Joan Massagué (2015) Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520(7547):368-72.

12. Willy Hugo*, Hubing Shi*, Lu Sun*, Marco Piva*, ChunYing Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, Antoni Ribas, and Roger S. Lo (2015) Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell 162(6):1271-85.

     *These authors contributed equally to this work.

 

联系方式:

Emailshihubing77@sina.com

 

生物治疗国家重点实验室 管理入口
地址:中国四川成都高朋大道科园四路一号 邮编:610041